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Background: Umbilical cord blood (UCB) is a stem cell
source for patients without matched sibling or unrelated
donors undergoing hematopoietic stem cell transplantation
(HSCT). Pre-engraftment syndrome (PES) is characterized by
unexplained fever and/or skin rash occurring at or prior to
neutrophil recovery in UCB HSCT patients. Few studies have
described the clinical features of PES and outcomes related
to development of acute graft-versus-host disease (aGVHD)
and overall survival. Though skin rash occurs in the majority
of patients with PES, little is known regarding the
morphology, anatomic location, or histology of cutaneous
PES. We aimed to identify these features in a series of pa-
tients with PES.
Methods:We retrospectively examined a series of UCB HSCT
patients who developed PES, deﬁned as non-infectious fever
and skin rash occurring before neutrophil engraftment. Data
collected included skin lesion morphology and anatomic
location, skin biopsy histopathology, concomitant clinical
features, and outcome.
Results: Four cases were reviewed and analyzed. 3 pa-
tients were female and 1 was male with mean age of
42 years (range 25-65). Conditions requiring HSCT
included peripheral T-cell lymphoma, hepatosplenic T-cell
lymphoma, myelodysplastic syndrome, and acute myeloid
leukemia.
Skin rash onset ranged from day +10 to +15 post-HSCT
with absolute neutrophil count of 0 to 100 cells/mm3. Lesion
morphology was described as morbilliform with follicular
accentuation (2/4), conﬂuent erythema with follicular
accentuation (1/4), and patchy erythema (1/4). Affected body
surface area ranged from 7% to 60%. Histopathology
demonstrated interface dermatitis with necrotic keratino-
cytes in 3/4 patients and mild spongiosis with a superﬁcial
perivascular lymphohistiocytic inﬁltrate in 1 patient.
Concurrent diarrhea was present in 3/4 patients (75%)
and elevated liver transaminases occurred in 1/4 patients
(25%). 3/4 patients (75%) were treated with systemic corti-
costeroids at doses between 0.5 to 1 mg/kg/day. All patients
were diagnosed with aGVHD (3 intestinal, 1 cutaneous) be-
tween day +20 to +34 post-HSCT, and all have survived
without disease relapse.
Conclusion: In our PES case series, 3/4 patients developed a
morbilliform skin eruption with follicular accentuation, and
the predominant histologic description was interface
dermatitis with necrotic keratinocytes. These are the same
clinical and histologic features of cutaneous aGVHD. Sys-
temic corticosteroids were administered in 3/4 cases, how-
ever all patients developed aGVHD and achieved 90 day
relapse-free survival. Larger, prospective studies are needed
to better describe the morphologic and histologic features of
cutaneous PES to determine the clinical and prognostic sig-
niﬁcance of this condition, and how they differ from aGVHD.
The necessity of treating PES with systemic steroids needs to
be further delineated.409
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Graft-versus-host disease (GVHD) is a major cause of
morbidity and mortality in patients receiving stem cell
transplant. Extracorporeal photopheresis has demonstrated
efﬁcacy in a proportion of GVHD patients that are steroid
refractory. However, given the expense, the challenging
logistics, and unpredictable GVHD response to ECP, a pre-
dictive immune biomarker to assist with the selection of
patients to treat with ECP can make this treatment modality
more efﬁcacious and cost-effective. One of the challenges of
using leukocyte as biomarkers is that any single leukocyte
population does not adequately describe the immune sys-
tem. We have recently described an approach to charac-
terize the immune system in a comprehensive manner. We
have used a combination of whole blood quantitative ﬂow
cytometry and bioinformatics to generate immune proﬁles
among patients with GVHD who were prescribed ECP.
GVHD grading and clinical responses were conﬁrmed by
serial physical exams and review of medical records over a 6
month period. Response to ECP was deﬁned as a decrease in
clinical grade of GVHD (IBMTR and NIH consensus criteria)
at the end of treatment. Peripheral blood drawn prior to
initiation of ECP was used to generate a patient’s immune
phenotype by analyzing 33 lymphoid and myeloid surface
marker combinations by ﬂow cytometry. Immune pheno-
types from 27 age-matched healthy volunteers were used as
controls.
From July 2011 to April 2013, 20 patients were enrolled (3
aGVHD, 17 cGVHD). At the time of this abstract, 15 patients
were evaluable for treatment response, with 6 responders
and 9 non-responders (median time on treatment 5.28
months, range 0.25 e 6 months). Using multivariate analysis
by principal component analysis and unsupervised hierar-
chical clustering, we identiﬁed clustering patterns (immune
proﬁles) in the composite immune phenotypes of the GVHD
patients and controls. The healthy controls clustered
together into a single immune proﬁle. Four of the six re-
sponders clustered closely together and away from the 9
non-responders and healthy controls (Fig 1). Anova analysis
identiﬁed 21 individual markers that were different among
the clusters. Using non-parametricWilcoxon comparison, we
found that patients who responded to ECP had lower
numbers of lymphocytes (p¼2.5x10-12), CD4 T cells
(p¼0.002), CD4+CD69+ T cells (p¼0.02), and CD8+CTLA4+
(p¼1.8x10-5) than healthy controls and non-responders.
To our knowledge, this is the ﬁrst report of a bioinformatics
approach to comprehensively examine systemic immune
proﬁles of GVHD patients. Our results provide the proof-of-
concept for using this method to identify an immune proﬁle
as a predictive biomarker in the treatment of GVHD. Our data
supports the need for a larger study to deﬁnitively deﬁne the
immune proﬁles and validate this approach.
